These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 23486449)
1. In chemotherapy for lung cancer, sometimes less is more. Roeland E; Loprinzi C; Moynihan TJ; Smith TJ; Temel J J Natl Compr Canc Netw; 2013 Mar; 11(3):232-5. PubMed ID: 23486449 [No Abstract] [Full Text] [Related]
2. Palliative benefits of chemotherapy treatment in non-small cell lung cancer may be underappreciated. J Support Oncol; 2006 Feb; 4(2):61. PubMed ID: 16499116 [No Abstract] [Full Text] [Related]
3. Complexities of quality of life analysis in non-small cell lung cancer. Temel J J Support Oncol; 2007 Jan; 5(1):30-1. PubMed ID: 17265784 [No Abstract] [Full Text] [Related]
4. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress? Buccheri G Lung Cancer; 1994 Jul; 11(1-2):115-7. PubMed ID: 7521731 [No Abstract] [Full Text] [Related]
12. Gefitinib plus docetaxel in non-small-cell lung cancer. Singh N; Aggarwal AN Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980 [No Abstract] [Full Text] [Related]
13. Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all. Schiller JH; Ramalingam SS J Clin Oncol; 2009 Jul; 27(20):3265-7. PubMed ID: 19470911 [No Abstract] [Full Text] [Related]
14. Palliative chemotherapy for non-small cell lung cancer: a measured dose of reality. Kalemkerian GP J Support Oncol; 2007 Jan; 5(1):27-8. PubMed ID: 17265783 [No Abstract] [Full Text] [Related]
15. Chemotherapy for lung cancer. Locke I; Gillham CM N Engl J Med; 2002 May; 346(19):1498; author reply 1498. PubMed ID: 12000824 [No Abstract] [Full Text] [Related]
16. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010 [No Abstract] [Full Text] [Related]
20. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure? Socinski MA J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913 [No Abstract] [Full Text] [Related] [Next] [New Search]